October 23, 2023

Genomic Medicine x AI Startup Xcoo,Inc.
has formed with H.U. Group Holdings, Inc.
a business and capital alliance founded on the mutualcommitment toward providing analytical services
in the ﬁeld of next-generation genomics and omics medicine.

Tokyo, Japan, October 23, 2023 --- We are pleased to announce that Xcoo, Inc. have reached a memorandum ofunderstanding with SRL, Inc., a subsidiary of H.U. Group Holdings, Inc., with the aim of creating analysis services in※the ﬁeld of next-generation genomics and omics medicine . Additionally, we have conducted a third-party
allotment of new shares to MSF Capital Partners G.K. taking on the role of H.U. Group's corporate venture capitalfunction.
The Background and Purpose of the Capital Business Alliance
For over the last decade, we have been an active contributor in the vastly developing ﬁeld of genomic medicine.
Through our endeavors we remain committed to be the catalyst for the social adaptation of genomic information
based precision medicine.
Since 2019, when insurance coverage for cancer gene panel testing (comprehensive cancer genome proﬁling)
was put in effect, the clinical application of genomic medicine appears feasible in the upcoming years. However,even with this pivotal medical implementation, there will still remain a large population unable to appreciate its
beneﬁts. This group includes patients with variations of cancer that cannot be elucidated by traditional panel
testing, as well as those diagnosed with rare and intractable diseases that remain untreatable. To combat thesechallenges, whole-genome sequencing (WGS) is viewed as the paradigm shifting innovation for personalized
medicine, which has invoked government led initiatives such as the Action Plan for Whole Genome Analysis ofJapan.
We possesses industry leading information technologies capable of analyzing and visualizing genome sequence
data generated by next-generation sequencers. With these advanced tools paired with our reporting technology
to automatically collect, organize, and report information related to genetic variants and diseases, we provide
assistance to healthcare professionals in clinical settings. H.U. Group and SRL possess unique qualities such as
their nationwide sample collection network, testing techniques from sample receipt to analysis using next-generation sequencers, and highly automated operational capabilities. Through collaboration between Xcoo and SRL,
we aim to promote the creation and clinical implementation of next-generation genomics and omics medical
diagnostic systems that assist in medical decisions such as drug efﬁcacy prediction, prognosis prediction, monitoring, and prevention. Additionally, Xcoo has strengthened its ﬁnancial foundation through investment from MSF.
Through this partnership, Xcoo, SRL, and H.U. Group plan to jointly provide a one-stop whole-genome analysis
service from sample receipt to reporting in an effort to assist patients with diseases and the healthcare professionals who care for them. We are dedicated in our contribution to the development of next-generation genomicand omics medicine as well as our growth as a business enterprise.

1/2

October 23, 2023

Strive to create a one-stop solution
for next-generation genomics and omics medicine
H.U. Group Holdings, Inc.

Xcoo, Inc.

※Genomic and Omics Medicine: Genomic medicine is a rapidly advancing ﬁeld that utilizes an individual's
genetic information to be able to prevent, diagnose, treat, and prognose various diseases, including cancer andrare diseases. Omics medicine encompasses comprehensive analysis of various biomolecules such as DNA, RNA,
proteins, and metabolites, and leverages this information for medical purposes. Genomic and omics medicine,which extends genomic medicine to omics medicine, is expected to promote the realization of personalized
precision medicine, offering the potential for the next generation of ﬁnely-tuned healthcare.
About Xcoo
A start-up company originating from the University of Tokyo, specialized in genome analysis and bioinformatics.
Xcoo has been developing and operating Chrovis, a total solution software for genomic and bioinformatics
analyses. The company has received numerous startup-related awards, including the MEXT Ministerʼs Award at
Adcademic Startups 2019. Chrovis Clinical Annotation Cancer Genome Reporting (tentative name) has been
designated for priority review by the Ministry of Health, Labor and Welfare concerning Software as a MedicalDevice (SaMD).
Headquarters： Headquarters : 2-40-8, Hongo, Bunkyo-ku, Tokyo 113-0033 JAPAN
CEO： Kunihiro Nishimura, Ph.D.
Established： April, 2011
Web site： https://xcoo.co.jp/
Xcooʼs Business： ・Development and operation of Chrovis, a total solution for genome and bioinformatics
analysis・Development of systems for high-speed data processing by parallel and distributed
computing・Development of systems for data analysis/visualization based on state-of-the-art algorithms
Recruitment information
We, Xcoo, are recruiting engineers and other professionals who are willing to assist in bridging information
technology toward social implementation along with us. To accomplish this, we have our business concept isfounded in, "organizing and analyzing large volumes of complex information (data intelligence), presenting themin a format that is comprehensable to any person (visualization), and ultimately leading to actions (decision-making). We welcome those who could share our mission and are willing to take on challenges together with ourhighly-skilled engineers and other professional staff.
Web site： https://xcoo.co.jp/recruit.html
Contact us
PR Team： pr@xcoo.jp
2/2